FDA shakes up weight loss market
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer in shortage after nearly two years. Pharmacies that sold unbranded copies of those drugs are mounting a coordinated effort to reverse this decision,
Mounjaro will soon be available as a weight loss treatment on the NHS. Here's what that means for patients
The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously,
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Rivals fight for right to sell weight loss drugs
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between
Weight-loss drug Wegovy to hit market on Tuesday
Weight-loss drug Wegovy will go on sale in Korea on Tuesday, with the much-anticipated injectable drug available for order through Zeullig Pharma Korea.
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
The weight loss drug with a waitlist
Sky News has revealed thousands of people with severe obesity are being denied access to effective treatment, partly because of a slow NHS rollout of the weight loss jab Wegovy.
Weight loss drugs have one big issue; These companies want to fix it
Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).
STAT3d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
STAT2d
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
Page Six4d
Celebrities on Ozempic: All the stars who’ve used weight-loss drugs
Spelling explained she was at 160 pounds when she tried the weight loss medication to slim back down to 120 pounds. She leaned off Mounjaro in January 2024 after reaching her goal weight.
Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...